Monday Market Minute | Nov 16, 2020
Moderna reports 94.5% vaccine efficacy, reinforcing the economic recovery thesis and improving the forward outlook across Canadian private market sectors.
What Moved
One week after Pfizer's announcement, Moderna reported 94.5% efficacy in its vaccine trial — confirming that multiple effective vaccines would be available for mass distribution. Markets rallied again, though less dramatically than the initial Pfizer reaction. The TSX pushed toward 17,000. Oil continued climbing. Bond yields rose further. The dual-vaccine confirmation removed the key risk that the first announcement was an outlier. Canada secured supply agreements with both manufacturers, with distribution expected to begin in December for priority populations. The pandemic endgame was no longer speculative.
Why It Matters
A second highly effective vaccine reduced the binary risk that had concerned private market investors. With two validated vaccines plus additional candidates in late-stage trials, the probability of a prolonged pandemic fell sharply. For private credit managers, improved economic certainty reduced the tail risk of additional credit deterioration. MIC lenders could underwrite with greater confidence in forward collateral values. PE investors could model revenue recovery with more conviction. The shift from uncertainty to visibility was a key unlock for private market deployment and valuation.
Signal to Watch
Track vaccine distribution logistics and provincial allocation plans. The speed of population-level immunization would determine the timeline for full economic normalization — the key variable for recovery-dependent private market holdings.